Innate and Adaptive Immune Responses in Asthma

Overview

Journal Nat Med

Specialties General Medicine
Molecular Biology

Date 2012 May 8

PMID 22561831

Citations 367

Authors

Stephen T Holgate

Affiliations

Soon will be listed here.

Abstract

The recognition that asthma is primarily an inflammatory disorder of the airways associated with T helper type 2 (T(H)2) cell-dependent promotion of IgE production and recruitment of mast cells and eosinophils has provided the rationale for disease control using inhaled corticosteroids and other anti-inflammatory drugs. As more has been discovered about the cytokine, chemokine and inflammatory pathways that are associated with T(H)2-driven adaptive immunity, attempts have been made to selectively inhibit these in the hope of discovering new therapeutics as predicted from animal models of allergic inflammation. The limited success of this approach, together with the recognition that asthma is more than allergic inflammation, has drawn attention to the innate immune response in this disease. Recent advances in our understanding of the sentinel role played by innate immunity provides new targets for disease prevention and treatment. These include pathways of innate stimulation by environmental or endogenous pathogen-associated molecular patterns (PAMPs) and danger-associated molecular patterns (DAMPs) to influence the activation and trafficking of DCs, innate sources of cytokines, and the identification of new T cell subsets and lymphoid cells.

Citing Articles

Social vulnerability and asthma-related emergency medical services in Illinois.

Geiger S, Khaium M, Gustafson E, Shapiro M, Keeley S, Johnson C Front Public Health. 2025; 13:1521545.

PMID: 40078769 PMC: 11897263. DOI: 10.3389/fpubh.2025.1521545.

An Updated Review on the Use of Noninvasive Respiratory Supports in the Management of Severe Asthma Exacerbations.

Cuttone G, La Via L, Pappalardo F, Sorbello M, Paterno D, Piattoli M Medicina (Kaunas). 2025; 61(2).

PMID: 40005443 PMC: 11857382. DOI: 10.3390/medicina61020328.

Incidence and risk factors of serious infections occurred in patients with lung cancer following immune checkpoint blockade therapy.

Wang X, Wu Y, Hu W, Zhang J BMC Cancer. 2025; 25(1):307.

PMID: 39979857 PMC: 11843754. DOI: 10.1186/s12885-025-13743-7.

Repeated and alternate stimulations with dsRNA and SEB alter responses in macrophages and epithelial cells.

Choi J, Kim Y, Kim M, Kang M, Hwang Y, Yoon J World Allergy Organ J. 2025; 18(2):101026.

PMID: 39925983 PMC: 11804812. DOI: 10.1016/j.waojou.2025.101026.

IL-33/ST2 axis in diverse diseases: regulatory mechanisms and therapeutic potential.

Sheng F, Li M, Yu J, Yang S, Zou L, Yang G Front Immunol. 2025; 16:1533335.

PMID: 39925809 PMC: 11802536. DOI: 10.3389/fimmu.2025.1533335.

References

van Panhuys N, Prout M, Forbes E, Min B, Paul W, Le Gros G . Basophils are the major producers of IL-4 during primary helminth infection. J Immunol. 2011; 186(5):2719-28. PMC: 3488853. DOI: 10.4049/jimmunol.1000940. View

Busse W, Israel E, Nelson H, Baker J, Charous B, Young D . Daclizumab improves asthma control in patients with moderate to severe persistent asthma: a randomized, controlled trial. Am J Respir Crit Care Med. 2008; 178(10):1002-8. DOI: 10.1164/rccm.200708-1200OC. View

Hilty M, Burke C, Pedro H, Cardenas P, Bush A, Bossley C . Disordered microbial communities in asthmatic airways. PLoS One. 2010; 5(1):e8578. PMC: 2798952. DOI: 10.1371/journal.pone.0008578. View

Veldhoen M, Uyttenhove C, Van Snick J, Helmby H, Westendorf A, Buer J . Transforming growth factor-beta 'reprograms' the differentiation of T helper 2 cells and promotes an interleukin 9-producing subset. Nat Immunol. 2008; 9(12):1341-6. DOI: 10.1038/ni.1659. View

Kon O, Sihra B, Loh L, Barkans J, Compton C, Barnes N . The effects of an anti-CD4 monoclonal antibody, keliximab, on peripheral blood CD4+ T-cells in asthma. Eur Respir J. 2001; 18(1):45-52. DOI: 10.1183/09031936.01.00064101. View

Holgate S . Pathophysiology of asthma: what has our current understanding taught us about new therapeutic approaches?. J Allergy Clin Immunol. 2011; 128(3):495-505. DOI: 10.1016/j.jaci.2011.06.052. View

Neill D, Wong S, Bellosi A, Flynn R, Daly M, Langford T . Nuocytes represent a new innate effector leukocyte that mediates type-2 immunity. Nature. 2010; 464(7293):1367-70. PMC: 2862165. DOI: 10.1038/nature08900. View

Ege M, Frei R, Bieli C, Schram-Bijkerk D, Waser M, Benz M . Not all farming environments protect against the development of asthma and wheeze in children. J Allergy Clin Immunol. 2007; 119(5):1140-7. DOI: 10.1016/j.jaci.2007.01.037. View

Kato A, Favoreto Jr S, Avila P, Schleimer R . TLR3- and Th2 cytokine-dependent production of thymic stromal lymphopoietin in human airway epithelial cells. J Immunol. 2007; 179(2):1080-7. PMC: 2220044. DOI: 10.4049/jimmunol.179.2.1080. View

10.

Baelder R, Fuchs B, Bautsch W, Zwirner J, Kohl J, Hoymann H . Pharmacological targeting of anaphylatoxin receptors during the effector phase of allergic asthma suppresses airway hyperresponsiveness and airway inflammation. J Immunol. 2005; 174(2):783-9. DOI: 10.4049/jimmunol.174.2.783. View

11.

Wingender G, Rogers P, Batzer G, Lee M, Bai D, Pei B . Invariant NKT cells are required for airway inflammation induced by environmental antigens. J Exp Med. 2011; 208(6):1151-62. PMC: 3173256. DOI: 10.1084/jem.20102229. View

12.

Willart M, Lambrecht B . The danger within: endogenous danger signals, atopy and asthma. Clin Exp Allergy. 2008; 39(1):12-9. DOI: 10.1111/j.1365-2222.2008.03118.x. View

13.

Shimbara A, Christodoulopoulos P, Olivenstein R, Nakamura Y, Levitt R, Nicolaides N . IL-9 and its receptor in allergic and nonallergic lung disease: increased expression in asthma. J Allergy Clin Immunol. 2000; 105(1 Pt 1):108-15. DOI: 10.1016/s0091-6749(00)90185-4. View

14.

Jacquet A . Interactions of airway epithelium with protease allergens in the allergic response. Clin Exp Allergy. 2010; 41(3):305-11. DOI: 10.1111/j.1365-2222.2010.03661.x. View

15.

Alvarez-Quiroga C, Abud-Mendoza C, Doniz-Padilla L, Juarez-Reyes A, Monsivais-Urenda A, Baranda L . CTLA-4-Ig therapy diminishes the frequency but enhances the function of Treg cells in patients with rheumatoid arthritis. J Clin Immunol. 2011; 31(4):588-95. DOI: 10.1007/s10875-011-9527-5. View

16.

Rabinovitch N, Liu A, Zhang L, Rodes C, Foarde K, Dutton S . Importance of the personal endotoxin cloud in school-age children with asthma. J Allergy Clin Immunol. 2005; 116(5):1053-7. DOI: 10.1016/j.jaci.2005.08.045. View

17.

Yano H, Ishida T, Inagaki A, Ishii T, Ding J, Kusumoto S . Defucosylated anti CC chemokine receptor 4 monoclonal antibody combined with immunomodulatory cytokines: a novel immunotherapy for aggressive/refractory Mycosis fungoides and Sezary syndrome. Clin Cancer Res. 2007; 13(21):6494-500. DOI: 10.1158/1078-0432.CCR-07-1324. View

18.

Castro M, Mathur S, Hargreave F, Boulet L, Xie F, Young J . Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. Am J Respir Crit Care Med. 2011; 184(10):1125-32. DOI: 10.1164/rccm.201103-0396OC. View

19.

McWilliam A, Nelson D, Thomas J, Holt P . Rapid dendritic cell recruitment is a hallmark of the acute inflammatory response at mucosal surfaces. J Exp Med. 1994; 179(4):1331-6. PMC: 2191461. DOI: 10.1084/jem.179.4.1331. View

20.

Baines K, Simpson J, Bowden N, Scott R, Gibson P . Differential gene expression and cytokine production from neutrophils in asthma phenotypes. Eur Respir J. 2009; 35(3):522-31. DOI: 10.1183/09031936.00027409. View